Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
XERS 
Xeris Pharmaceuticals Inc (XERS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: XERS (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $6.3
1 Year Target Price $6.3
| 4 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 96.4% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 760.74M USD | Price to earnings Ratio - | 1Y Target Price 6.3 |
Price to earnings Ratio - | 1Y Target Price 6.3 | ||
Volume (30-day avg) 6 | Beta 0.91 | 52 Weeks Range 2.10 - 6.07 | Updated Date 07/4/2025 |
52 Weeks Range 2.10 - 6.07 | Updated Date 07/4/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.29 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -20.25% | Operating Margin (TTM) -5.14% |
Management Effectiveness
Return on Assets (TTM) -3.14% | Return on Equity (TTM) -617.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 971047250 | Price to Sales(TTM) 3.42 |
Enterprise Value 971047250 | Price to Sales(TTM) 3.42 | ||
Enterprise Value to Revenue 4.36 | Enterprise Value to EBITDA -3.36 | Shares Outstanding 160155008 | Shares Floating 152803886 |
Shares Outstanding 160155008 | Shares Floating 152803886 | ||
Percent Insiders 4.19 | Percent Institutions 54.5 |
Upturn AI SWOT
Xeris Pharmaceuticals Inc
Company Overview
History and Background
Xeris Pharmaceuticals, Inc. was founded in 2005. The company focuses on developing and commercializing ready-to-use injectable and infusible drug formulations for various therapies, often using their XeriSol and XeriJect technology platforms.
Core Business Areas
- Endocrinology: Focuses on therapies for diabetes, including treatments for severe hypoglycemia and related conditions.
- Neurology: Developing products to treat neurological conditions, such as epilepsy.
- Partnerships: Collaboration with other pharmaceutical companies to utilize Xeris's drug delivery technologies.
Leadership and Structure
Paul R. Edick is the Chairman and CEO. The company has a typical pharmaceutical organizational structure with departments for research and development, commercial operations, finance, and administration.
Top Products and Market Share
Key Offerings
- Gvoke (glucagon injection): Gvoke is an injectable glucagon used to treat severe hypoglycemia in adults and children with diabetes. The product competes with traditional glucagon kits that require reconstitution. As of 2023, Gvoke's market share is growing but remains behind Eli Lilly's Baqsimi. Competitors include Eli Lilly (LLY) (Baqsimi) and Amphastar Pharmaceuticals (AMPH).
- Keveyis: Keveyis is the first and only FDA-approved therapy for hyperkalemic periodic paralysis (HPP) and hypokalemic periodic paralysis (HOKPP). There are generics for HPP and HOKPP so Keveyis has to compete with those.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated, with a focus on innovation, clinical trials, and regulatory approvals. The market for diabetes and endocrine therapies is substantial and growing.
Positioning
Xeris is positioning itself as a leader in ready-to-use injectable therapeutics, particularly in diabetes management. Its competitive advantage lies in its proprietary drug delivery technologies.
Total Addressable Market (TAM)
The total addressable market for diabetes treatments is estimated to be in the billions of dollars. Xeris is positioned to capture a portion of this market with its innovative products. The market for Keveyis is more niche, in the millions, focused on a rare disease.
Upturn SWOT Analysis
Strengths
- Proprietary drug delivery technologies (XeriSol, XeriJect)
- FDA-approved products (Gvoke, Keveyis)
- Focus on underserved patient populations
- Experienced management team
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Reliance on key products
- Market penetration challenges against established competitors
- History of operating losses
Opportunities
- Expansion of product pipeline through internal development and partnerships
- Geographic expansion into international markets
- Increased adoption of ready-to-use injectable therapies
- Potential for acquisitions or collaborations
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and changes in healthcare policies
- Generic erosion of existing products
- Product liability risks
Competitors and Market Share
Key Competitors
- LLY
- AMPH
- TEVA
Competitive Landscape
Xeris advantages include proprietary technologies and a focus on ready-to-use injectables. Disadvantages include limited resources compared to larger competitors like Eli Lilly.
Growth Trajectory and Initiatives
Historical Growth: Xeris has shown revenue growth in recent years, driven by sales of Gvoke and Keveyis.
Future Projections: Future growth depends on product adoption, pipeline development, and market expansion. Analyst estimates vary.
Recent Initiatives: Recent initiatives include expanding sales and marketing efforts for Gvoke and Keveyis, advancing pipeline programs, and seeking strategic partnerships.
Summary
Xeris Pharmaceuticals is a specialty pharmaceutical company focusing on injectable and infusible drug delivery. Its approved products, Gvoke and Keveyis, are driving revenue growth. Xeris faces competition from larger pharmaceutical companies and needs to continue to innovate. They are a medium strength company that should focus on expanding the total addressable market for their current products.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry News
- Company Website
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market conditions and company performance are subject to change. Consult a financial professional before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Xeris Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Chicago, IL, United States | ||
IPO Launch date 2018-06-21 | CEO & Director Mr. John P. Shannon | ||
Sector Healthcare | Industry Biotechnology | Full time employees 394 | Website https://www.xerispharma.com |
Full time employees 394 | Website https://www.xerispharma.com | ||
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.